Janet B. McGill
Washington University in St. Louis
212 Papers
924 Citations
Janet B. McGill is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 61, co-authored 182 publications.
Chat about Author
Papers
Differential Effects of β-Blockers on Albuminuria in Patients With Type 2 Diabetes
George L. Bakris,Vivian Fonseca,Richard E. Katholi,Janet B. McGill,Franz H. Messerli,Robert A. Phillips,Philip Raskin,Jackson T. Wright,Brian Waterhouse,Mary Ann Lukas,Karen M. Anderson,David S.H. Bell +11 more
TL;DR: Blockers have differential effects on microalbuminuria in the presence of renin-angiotensin system blockade, which cannot be explained by effects on blood pressure or &agr;1-antagonism but may relate to antioxidant properties of carvedilol.
Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
Janet B. McGill,Hannele Yki-Järvinen,Susanne Crowe,Hans-Juergen Woerle,Maximilian von Eynatten +4 more
TL;DR: Adding linagliptin to insulin in type 2 diabetes mellitus patients with chronic kidney disease improved glucose control and was well tolerated.
Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial
Roy W. Beck,Tonya D Riddlesworth,Katrina J. Ruedy,Craig Kollman,Andrew J Ahmann,Richard M Bergenstal,Anuj Bhargava,Bruce W. Bode,Stacie Haller,Davida F. Kruger,Janet B. McGill,William H. Polonsky,David Price,Elena Toschi,Howard Wolpert,Astrid Atakov-Castillo,Edvina Markovic,Stephen Aronoff,Satanya Brooks,Gloria Martinez,Angela Mendez,Theresa Dunnam,Kathy Fitzgerald,Diana Wright,Teck Khoo,Pierre Theuma,Tara Herrold,Debra Thomsen,Richard M. Bergenstal,Kathleen McCann,Arlene Monk,Char Ashanti,David Liljenquist,Heather Judge,Jean Halford,Davida Kruger,Shiri Levy,Arti Bhan,Terra Cushman,Lameka Dawson,Heather Remtema,Fawn Wolf,James Neifing,Jennifer Murdoch,Susan Staat,Tamara Mayfield,Andrew J. Ahmann,Bethany Klopfenstein,Farahnaz Joarder,Kathy Hanavan,Jessica R. Castle,Diana Aby-Daniel,Victoria Morimoto,Donald DeFrang,Bethany Wollam,Janet B. McGill,Olivia Jordan,Carol Recklein,Mark Kipnes,Terri Ryan,Bruce W. Bode,Jennifer Boyd,Nitin Rastogi,Katherine Lindmark,William Biggs,Lorena Sandoval,Robin Eifert,Becky Cota,Quang Nguyen,Alejandra Martinez,Cathy Duran,Scott Segel,David Sutton,Miguel Roura,Rebecca Rosenwasser,Jennifer McElveen,Emily Knisely,Anne Johnson,A. Ola Odugbesan,Karla Wardell,Carolyn Paulus,Jack Wahlen,Jon Winkfield,Hilary Wahlen,Emily Hepworth,David Winkfield,Sue Owens,Steven Leichter,Emily Evans,Sarah Konigsberg,Jennifer Rahman,Linda Gaudiani,Natalie Woods,Jesse Cardozo,Kate Wheeler,Jennifer Kane,Terri Eubanks,Katrina Ruedy,Tonya Riddlesworth,Thomas Mouse,Eileen Casal,Claudia Graham +101 more
TL;DR: The findings show that glycaemic control measured by time in the glucose range of 70-180 mg/dL (3·9-10·0 mmol/L) is improved by initiation of CSII in adults with type 1 diabetes.
Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data
Maryam Afkarian,Sarit Polsky,Afshin Parsa,Ronnie Aronson,Maria Luiza Caramori,David Z.I. Cherney,Jill P. Crandall,Ian H. de Boer,Tom Elliott,Andrzej T. Galecki,Allison B. Goldfine,J. Sonya Haw,Irl B. Hirsch,Amy B. Karger,Ildiko Lingvay,David M. Maahs,Janet B. McGill,Mark E. Molitch,Bruce A. Perkins,Rodica Pop-Busui,Marlon Pragnell,Sylvia E. Rosas,Peter Rossing,Peter Rossing,Peter A. Senior,Ronald J. Sigal,Catherine Spino,Katherine R. Tuttle,Guillermo E. Umpierrez,Amisha Wallia,Ruth S. Weinstock,Chun Yi Wu,Michael Mauer,Alessandro Doria +33 more
TL;DR: Preventing Early Renal Loss in Diabetes (PERL) evaluates whether lowering SUA with allopurinol slows glomerular filtration rate (GFR) loss in people with type 1 diabetes (T1D) and mild to moderate DKD, with or without albuminuria.
Efficacy and Safety of Combination Therapy Repaglinide plus metformin versus nateglinide plus metformin
Philip Raskin,Leslie Klaff,Janet B. McGill,Stephen A. South,Priscilla Hollander,Naum Khutoryansky,Paula M Hale +6 more
TL;DR: The addition of repaglinide to metformin therapy resulted in reductions of HbA(1c) and FPG values that were significantly greater than the reductions observed for addition of nateglinide.